Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31019636 | 0.89 | ADRB2 (0.68) | ADRB2ADRB1CYP1A2TSHRADRB3 | |
| Hydrochloric Acid SCHEMBL31148312 | 0.87 | ADRB2 (0.76) | ADRB2ADRB1CYP1A2TSHRADRB3 | |
| SCHEMBL30234234 | 0.85 | ADRB2 (0.59) | ADRB2ADRB1CYP1A2TSHRADRB3 | |
| SCHEMBL21793189 | 0.85 | ADRB2 (0.76) | ADRB2ADRB1CYP1A2TSHRADRB3 | |
| Practolol SCHEMBL39925 | 0.84 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRADRB3 | |
| Practolol SCHEMBL6509191 | 0.84 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRADRB3 | |
| Practolol SCHEMBL39926 | 0.84 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2TSHRADRB3 | |
| Practolol SCHEMBL9117980 | 0.83 | ADRB2 (0.97) | ADRB2ADRB1CYP1A2TSHRADRB3 | |
| SCHEMBL14307663 | 0.83 | ADRB2 (0.78) | ADRB2ADRB1CYP1A2TSHRADRB3 | |
| SCHEMBL10877050 | 0.83 | KMT2A (0.70) | ADRB2ADRB1CYP1A2TSHRADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170098-A1 | MOLECULAR JACKHAMMER FOR MECHANICAL DESTRUCTION OF CELLULAR STRUCTURE | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4482572-A2 | MOLECULAR JACKHAMMER FOR MECHANICAL DESTRUCTION OF CELLULAR STRUCTURE | William Marsh Rice University (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024148293-A1 | CHARGED PI-CONJUGATED MOLECULES FOR THE TREATMENT OF MICROBIAL INFECTIONS | WILLIAM MARSH RICE UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023164663-A2 | MOLECULAR JACKHAMMER FOR MECHANICAL DESTRUCTION OF CELLULAR STRUCTURE | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230032082-A1 | SPATIAL BARCODING | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170098-A1 | MOLECULAR JACKHAMMER FOR MECHANICAL DESTRUCTION OF CELLULAR STRUCTURE | HSPE1, ANXA4, MDH1 | ADRB2 4603/4885ADRB1 4613/4885CYP1A2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.